PMID- 27588390
OWN - NLM
STAT- MEDLINE
DCOM- 20170323
LR  - 20200106
IS  - 2299-5684 (Electronic)
IS  - 1734-1140 (Linking)
VI  - 68
IP  - 6
DP  - 2016 Dec
TI  - A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic 
      events and complementary predictors of survival in lung cancer patients treated 
      with EGFR tyrosine kinase inhibitors.
PG  - 1140-1148
LID - S1734-1140(16)30090-1 [pii]
LID - 10.1016/j.pharep.2016.07.003 [doi]
AB  - BACKGROUND: Progression of lung cancer is associated with some abnormalities in 
      coagulation. The aim of the study was to determine the predictive and prognostic 
      value of changes in D-dimer concentration in non-small cell lung cancer (NSCLC) 
      patients on anti-EGFR targeted therapy. METHODS: The analysis included fifty two 
      NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or 
      gefitinib. All clinical data were collected before treatment and after 2 cycles 
      (60days) of therapy and correlated with progression free and overall survival 
      (PFS, OS). RESULTS: Two iatrogenic events were noted within the first 60days of 
      anti-EGFR treatment: typical skin rash in 38 (73.1%) and a decrease in D-dimer 
      concentration in 26 (50%) patients. Multivariate analysis revealed a decrease of 
      D-dimer concentration as the strongest factor associated with longer PFS 
      (HR=0.39; 95%CI: 0.16-0.91; p=0.029) and OS (HR=0.33; 95%CI: 0.13-0.82, p=0.017) 
      independently of skin rash, baseline level of D-dimer and other clinical 
      characteristics. Coexisting a decrease in D-dimer concentration with an 
      occurrence of skin rash correlated significantly with the positive objective 
      response after 60days of anti-EGFR therapy (p=0.0175) and indicated the longest 
      PFS (HR=0.31; 95%CI: 0.16-0.60, p=0.0005) as well as OS (HR=0.30; 95%CI: 
      0.15-0.59, p=0.0005). CONCLUSION: Adverse events may predict the outcomes of 
      cancer patients. Apart from skin rash, change in D-dimer concentration may be 
      valuable parameter in creation of predictive and prognostic models in NSCLC 
      patients receiving anti-EGFR targeted therapy.
CI  - Copyright (c) 2016. Published by Elsevier Urban & Partner Sp. z o.o.
FAU - Zaborowska-Szmit, Magdalena
AU  - Zaborowska-Szmit M
AD  - Lung & Thoracic Tumors Department, The Maria Sklodowska-Curie Memorial Cancer 
      Centre & Institute of Oncology, Warszawa, Poland.
FAU - Kowalski, Dariusz M
AU  - Kowalski DM
AD  - Lung & Thoracic Tumors Department, The Maria Sklodowska-Curie Memorial Cancer 
      Centre & Institute of Oncology, Warszawa, Poland.
FAU - Piorek, Aleksandra
AU  - Piorek A
AD  - Lung & Thoracic Tumors Department, The Maria Sklodowska-Curie Memorial Cancer 
      Centre & Institute of Oncology, Warszawa, Poland.
FAU - Krzakowski, Maciej
AU  - Krzakowski M
AD  - Lung & Thoracic Tumors Department, The Maria Sklodowska-Curie Memorial Cancer 
      Centre & Institute of Oncology, Warszawa, Poland.
FAU - Szmit, Sebastian
AU  - Szmit S
AD  - Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of 
      Postgraduate Medical Education, European Health Centre Otwock, Otwock, Poland. 
      Electronic address: s.szmit@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20160720
PL  - Switzerland
TA  - Pharmacol Rep
JT  - Pharmacological reports : PR
JID - 101234999
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - 0 (fibrin fragment D)
RN  - DA87705X9K (Erlotinib Hydrochloride)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Biomarkers, Tumor/blood
MH  - Carcinoma, Non-Small-Cell Lung/*blood/diagnosis/drug therapy
MH  - Disease-Free Survival
MH  - ErbB Receptors/*antagonists & inhibitors/metabolism
MH  - Erlotinib Hydrochloride/adverse effects/therapeutic use
MH  - Exanthema/*blood/chemically induced/diagnosis
MH  - Female
MH  - Fibrin Fibrinogen Degradation Products/*metabolism
MH  - Gefitinib
MH  - Humans
MH  - Iatrogenic Disease
MH  - Lung Neoplasms/*blood/diagnosis/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Predictive Value of Tests
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Quinazolines/adverse effects/therapeutic use
MH  - Survival Rate/trends
OTO - NOTNLM
OT  - D-dimer
OT  - EGFR inhibitors
OT  - Lung cancer
OT  - Overall survival
OT  - Progression free survival
OT  - Skin rash
EDAT- 2016/09/03 06:00
MHDA- 2017/03/24 06:00
CRDT- 2016/09/03 06:00
PHST- 2016/03/25 00:00 [received]
PHST- 2016/06/28 00:00 [revised]
PHST- 2016/07/18 00:00 [accepted]
PHST- 2016/09/03 06:00 [pubmed]
PHST- 2017/03/24 06:00 [medline]
PHST- 2016/09/03 06:00 [entrez]
AID - S1734-1140(16)30090-1 [pii]
AID - 10.1016/j.pharep.2016.07.003 [doi]
PST - ppublish
SO  - Pharmacol Rep. 2016 Dec;68(6):1140-1148. doi: 10.1016/j.pharep.2016.07.003. Epub 
      2016 Jul 20.